Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Sipuleucel-T Studies Support Earlier Use, Reveal Potential Biomarker

July 25th 2012

Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.

Black Men With Advanced Prostate Cancer May Benefit From Sipuleucel-T

July 18th 2012

Preliminary data suggest a promising role for sipuleucel-T as a treatment for African-American men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Taplin on Abiraterone Acetate's Mechanism of Action

July 17th 2012

Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Abiraterone Acetate's Mechanism of Action

Healthy Lifestyle Improves Sexual Function Post-Prostatectomy

July 17th 2012

Patients with prostate cancer can expect better sexual function after a robotic-assisted radical prostatectomy (RARP) if they maintain a healthy lifestyle.

The Urology Group: Balancing Expansion With Commitment to the Community

July 13th 2012

In tough economic times when many medical practices have scaled back or even shut down, The Urology Group has flourished.

Bone Health Programs in Urology Practices Deliver Continuity of Care

July 12th 2012

Spurred by the desire to provide the full spectrum of care to prostate cancer patients, urologists across the country have begun to integrate bone health clinics into their practices.

Dr. Ryan on Neoadjuvant Abiraterone Acetate

July 11th 2012

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses Neoadjuvant Abiraterone Acetate

Marital Status Impacts Survival in Prostate Cancer Patients

July 11th 2012

Marital status is an independent predictor of disease-related mortality and overall mortality in men with prostate cancer.

Dr. Fong Discusses Immune Response to Sipuleucel-T

July 10th 2012

Dr. Lawrence Fong from University of California, San Francisco, Discusses Immune Response to Sipuleucel-T

Vitamin D Might Benefit Patients With Prostate Cancer

July 5th 2012

The cancer proliferation marker Ki-67 decreased significantly in men who took high-dose vitamin D in the weeks leading up to radical prostatectomy for localized prostate cancer.

Case-Based Discussion: Sequencing Prostate Cancer Therapy

July 3rd 2012

Case-based discussion on sequencing prostate cancer therapies for a 72-year-old man with a metastatic adenocarcinoma with small-cell components, a PSA score of 80, and a Gleason score of 10.

Dr. Shore on the Enzalutamide Mechanism of Action

June 28th 2012

Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses enzalutamide, a well tolerated oral therapy.

High Points and Hurdles: Immunotherapy Moves Forward

June 27th 2012

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Taplin on Neoadjuvant ADT Plus Hormonal Therapy

June 25th 2012

Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer.

Affirming the Promise of Enzalutamide: A New Opportunity for Integrative Care in Prostate Cancer

June 25th 2012

Enzalutamide seems poised to become an exciting addition to the growing list of novel therapies approved for the treatment of prostate cancer.

Novel Concepts Include New Agents, Combinations

June 19th 2012

Oncology specialists who treat patients with mCRPC can look forward to choosing from an expanding array of therapeutic tools, including regimens.

Dr. Ryan Discusses Sequencing Prostate Cancer Therapies

June 18th 2012

Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.

Four Later-Stage Immunotherapy Strategies Appear Promising

June 14th 2012

While many approaches to using immunotherapy for the treatment of prostate cancer are under study, four strategies currently in later-stage clinical development have emerged as the most promising.

Studies Crystallize Variable Impact of ADT-RT Combination Therapy

June 13th 2012

The results of several long-term clinical trials published last year clarify the role of combination ADT and RT in the treatment of men with prostate cancer.

IPCC Case-Based Discussion: How Should We Sequence Therapy?

June 12th 2012

Three case studies focused on how best to sequence therapy in prostate cancer were presented by Daniel P. Petrylak, MD, and discussed by a panel that included Robert Dreicer, MD, and Oliver Sartor, MD.